冠心病中西医发病机制及治疗研究进展
Research Progress on the Pathogenesis and Treatment of Coronary Heart Disease with Traditional Chinese and Western Medicine
DOI: 10.12677/tcm.2026.157366, PDF,   
作者: 刘宇锡:黑龙江中医药大学研究生院,黑龙江 哈尔滨;金 娟*:黑龙江中医药大学附属第一医院心血管病一科,黑龙江 哈尔滨
关键词: 冠心病中西医发病机制治疗方法Coronary Heart Disease Integrated Traditional Chinese and Western Medicine Pathogenesis Treatment Methods
摘要: 冠心病又称为冠状动脉粥样硬化性心脏病,是临床最常见的缺血性心血管疾病,因冠状动脉粥样硬化导致血管管腔狭窄、痉挛或闭塞,引发心肌缺血、缺氧甚至坏死,具有发病率高、致残率高、死亡率高、年轻化趋势显著等特点。研究显示,我国成年人冠心病患病率已达12.3%,每年心血管死亡患者中冠心病患者超60%,已成为威胁国民生命健康的首要慢性心血管疾病。目前西医认为,冠心病发病核心与脂质代谢紊乱、血管内皮损伤、慢性炎症反应、血小板异常活化、氧化应激及血管重构等多重因素密切相关。中医将冠心病归属于“胸痹”、“心痛”、“真心痛”等范畴,以气虚、阳虚、气阴两虚为本,以血瘀、痰浊、气滞、寒凝为标,病位在心,与肝、脾、肾三脏功能失调密切相关。本文汇总近年冠心病中西医发病机制及临床治疗研究进展,总结当前研究存在的问题,并展望未来发展方向,为冠心病临床防治提供理论依据与实践参考。
Abstract: Coronary heart disease, also known as coronary atherosclerotic heart disease, is the most common ischemic cardiovascular disease in clinical practice. It is caused by coronary atherosclerosis, leading to vascular lumen stenosis, spasm, or occlusion, which can trigger myocardial ischemia, hypoxia, and even necrosis. It is characterized by a high incidence rate, high disability rate, high mortality rate, and a significant trend towards younger patients. Studies show that the prevalence of coronary heart disease among adults in China has reached 12.3%, with coronary heart disease patients accounting for over 60% of cardiovascular deaths each year, making it the primary chronic cardiovascular disease threatening national life and health. Currently, Western medicine believes that the core pathogenesis of coronary heart disease is closely related to multiple factors such as lipid metabolism disorder, vascular endothelial injury, chronic inflammatory response, abnormal platelet activation, oxidative stress, and vascular remodeling. Traditional Chinese medicine categorizes coronary heart disease under terms such as “chest obstruction”, “heartache” and “true heartache” with qi deficiency, yang deficiency, and qi and yin deficiency as the root causes, and blood stasis, phlegm turbidity, qi stagnation, and cold coagulation as the superficial manifestations. The disease is located in the heart and is closely related to dysfunction of the liver, spleen, and kidney organs. This article summarizes recent research progress on the pathogenesis and clinical treatment of coronary heart disease in both Western and traditional Chinese medicine, highlights existing research issues, and looks forward to future development directions, providing theoretical basis and practical reference for the clinical prevention and treatment of coronary heart disease.
文章引用:刘宇锡, 金娟. 冠心病中西医发病机制及治疗研究进展[J]. 中医学, 2026, 15(7): 108-113. https://doi.org/10.12677/tcm.2026.157366

参考文献

[1] 朱爽, 郑娴. 中医药治疗冠心病稳定型心绞痛气虚血瘀证的研究进展[J]. 云南中医中药杂志, 2026, 47(5): 130-133.
[2] 李亚奇, 苗倩倩, 秦庆祝. 综合心理干预对冠心病介入治疗患者心理弹性及睡眠质量的影响[J]. 临床心身疾病杂志, 2026, 32(3): 46-50.
[3] 钟绍发, 彭奇萍, 田旺, 等. 芪苈强心胶囊联合重组人脑利钠肽治疗冠心病合并慢性心力衰竭患者对其心功能及心力衰竭指标的影响[J]. 检验医学与临床, 2026, 23(9): 1265-1270.
[4] 费梦懿, 叶夏莉. 老年冠心病患者焦虑抑郁、治疗依从性与社会支持水平[J]. 公共卫生与预防医学, 2026, 37(3): 163-167.
[5] 张落超, 王喜阳, 郭梦琳, 等. 老年冠心病患者NFKB1、IL-17A基因多态性与脂质代谢、炎症因子及冠脉狭窄程度的关系[J]. 中国老年学杂志, 2025, 45(16): 3841-3844.
[6] 陈芳桃. 尼可地尔片联合曲美他嗪治疗老年冠心病心绞痛的疗效及对血管内皮损伤和血脂的影响[J]. 心血管病防治知识, 2025, 15(24): 18-21.
[7] 高慧兰, 杨永春, 刘芳. 冠心宁对冠心病慢性心力衰竭患者炎症及心室重构指标的影响[J]. 中国卫生工程学, 2024, 23(3): 407-409.
[8] 李圳, 李娜, 柳营. 沙库巴曲缬沙坦钠与厄贝沙坦对冠心病心力衰竭患者心肌能量代谢、氧化应激的影响观察[J]. 黑龙江医药科学, 2026, 49(5): 121-123+127.
[9] 菅朋. 阿司匹林联合硫酸氢氯吡格雷治疗老年冠心病的效果分析[J]. 中国社区医师, 2024, 40(33): 50-52.
[10] 叶文锋, 苏良献, 黄杰雄. 他汀类药物联合英克司兰治疗冠心病合并原发性高胆固醇血症对血脂和血管内皮功能的影响以及心血管获益情况研究[J]. 北方药学, 2026, 23(1): 129-131.
[11] 郭辉. 美托洛尔在老年冠心病不稳定型心绞痛患者中的应用效果及药学分析[J]. 中国现代药物应用, 2026, 20(7): 75-78.
[12] 朱国平. 冠脉支架介入治疗冠心病患者的预后影响因素分析[J]. 智慧健康, 2025, 11(36): 155-158.
[13] 吴哲颖, 毛鑫羽, 勾梦涵, 等. 基于易水学派“温补脾肾”理论探讨老年冠心病的病因病机[J]. 基层中医药, 2025, 4(9): 63-67.
[14] 王建戬, 张国强, 庞菁. 血府逐瘀汤联合阿托伐他汀钙对痰瘀互结型冠心病患者血脂及微循环状态的影响[J]. 黑龙江医药, 2026, 39(2): 353-356.
[15] 李鑫鑫, 孙冬媛, 纪志刚, 等. 生脉散“异病同治”冠心病和心肌梗死的机制探讨[J]. 通化师范学院学报, 2025, 46(8): 48-59.
[16] 杨洪臣. 瓜蒌薤白半夏汤治疗冠心病痰浊内阻证患者的临床效果及心功能影响分析[J]. 内蒙古中医药, 2026, 45(4): 18-19.
[17] 白璐, 张立娜, 王雅琦. 炙甘草汤加减对老年冠心病合并心律失常患者cTnT、CK、BNP、CXCL9水平的影响[J]. 中国老年学杂志, 2025, 45(18): 4380-4383.
[18] 郑黎明, 曾斯璐, 曹华勇. 复方丹参滴丸的药理机制及在冠心病心绞痛中的临床应用研究进展[J]. 临床合理用药, 2026, 19(13): 160-163.